|
|
Article: Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing.
- Article from:
- PR Newswire
- Article date:
- August 27, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WAYNE, Pa., Aug. 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. , a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 21, 2009, it received a letter from Nasdaq stating that since it had not, as of the date of the letter, filed its 10-Q for the quarterly period ended June 30, 2009, it was then no longer in compliance with the rules for continued listing according to Listing Rule 5250(c)(1).
Encorium filed its Form 10-Q for the quarterly period ended June 30, 2009 on August 21, 2009. As a result, the ...
Related newspaper, magazine, and journal articles:
|
|
Article: Multiple Insiders of Encorium Group, Inc.(NasdaqCM: ...
M2 Presswire;
October 21, 2009 ;
586 words
... ... Multiple Insiders of Encorium Group, Inc.(NasdaqCM ... Multiple Insiders of Encorium Group, Inc.(NasdaqCM ... insidercow.com. About ENCO Encorium Group, Inc. designs and manages clinical trials for pharmaceutical ...
|
|